PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Arrowhead Pharmaceuticals, Inc.

USPTO PatentsView assignee record — 93 granted patents across 18 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Explore the portfolio See the ranking
93
Total patents granted
18
CPC technology areas
21.7
Avg claims per patent
+2%
5-year filing velocity

The verdict

Arrowhead holds 93 US patents across 18 technology areas — rank #3,875 of 50,000 tracked assignees.

#3,875
of 50,000 US assignees by volume
Top 16%
by Innovation Score (48.8/100)
21.7
avg claims per patent
+2%
filing velocity, last 5 yrs

Portfolio overview

Arrowhead Pharmaceuticals, Inc. has been granted 93 US utility patents between 2016 and 2025, placing Arrowhead Pharmaceuticals, Inc. at rank #3,875 across all assignees tracked by PlainPatent. This portfolio spans 18 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.7 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Arrowhead Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 48.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 47 grants, compared with 46 in the 2015–2019 window — a +2% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Arrowhead Pharmaceuticals, Inc.'s 21.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 18 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Arrowhead Pharmaceuticals, Inc. against peers pursuing similar technology classes.

How does Arrowhead compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Arrowhead holds 93 patents — placing it at rank #3,875 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Arrowhead's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

05101520 2016201720182019202020212022202320242025 5
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Arrowhead Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 11 11.8%
2017 11 11.8%
2018 15 16.1%
2019 9 9.7%
2020 11 11.8%
2021 9 9.7%
2022 7 7.5%
2023 6 6.5%
2024 9 9.7%
2025 5 5.4%

Which technologies does Arrowhead Pharmaceuticals, Inc. patent most?

Top 15 of 18 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Growing

Where it ranks

Overall rank by patents

#3,875

Across all tracked assignees

Innovation Score

48.8 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Arrowhead Pharmaceuticals, Inc. hold?
Arrowhead Pharmaceuticals, Inc. holds 93 US granted patents filed between 2016 and 2025, spanning 18 technology areas.
What is Arrowhead Pharmaceuticals, Inc.'s Innovation Score?
Arrowhead Pharmaceuticals, Inc. has an Innovation Score of 48.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Arrowhead Pharmaceuticals, Inc. focus on?
Arrowhead Pharmaceuticals, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 84 patents. The company has filed patents in 18 CPC subclasses total.
Is Arrowhead Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Arrowhead Pharmaceuticals, Inc.'s recent filing velocity is +2% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Arrowhead Pharmaceuticals, Inc.'s patents?
Arrowhead Pharmaceuticals, Inc.'s patents average 21.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Arrowhead Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Arrowhead's 93 grants land it in the top 16% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Arrowhead ranks #3,875 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12N — see who else leads that technology area. C12N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

C12N technology

Arrowhead Pharmaceuticals, Inc.'s primary CPC class — all holders and yearly trends
Top 50 patent holders

See where Arrowhead Pharmaceuticals, Inc. ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov